Study summary

Orforglipron brought average HbA1c to about 6.5% in early type 2 diabetes

ACHIEVE-1 trial (orforglipron) · 559 people, phase 3 · Published June 2025, New England Journal of Medicine

7.6%weight loss with the highest dose, vs 1.7% with placebo

What was tested

Orforglipron at three doses against placebo for 40 weeks in people with type 2 diabetes managed with diet and exercise only.

What they found

What it means

Supports orforglipron as an early, oral option.

N Engl J Med, via PubMed ↗ Trial record NCT05971940 ↗ ← Back to the outlook
Last reviewed 2026-11-16 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.